Workflow
Telix Pharmaceuticals Ltd(TLX)
icon
Search documents
TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm
GlobeNewswire News Room· 2025-08-23 13:36
Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Telix Pharmaceuticals Limited for possible violations of federal securities laws and unlawful business practices [1][2]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Telix to contact them to discuss their legal rights [1]. - On July 22, 2025, Telix received a subpoena from the U.S. Securities and Exchange Commission regarding disclosures related to its prostate cancer therapeutic candidates [2]. - Following the subpoena news, Telix's American Depositary Receipt (ADR) price dropped by $1.70, or 10.44%, closing at $14.58 per ADR on July 23, 2025 [2]. Group 2: Contact Information - Investors can reach out to Bragar Eagel & Squire for more information about the claims or their rights without any cost or obligation [3]. - Contact details for the law firm include phone number (212) 355-4648 and email investigations@bespc.com [6].
TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm
Prnewswire· 2025-08-21 08:05
LOS ANGELES, Aug. 21, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Telix Pharmaceuticals Limited ("Telix" or "the Company") (NASDAQ: TLX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Telix disclosed on July 22, 2025, that it had received a subpoena from ...
Telix Pharmaceuticals Ltd(TLX) - 2025 H1 - Earnings Call Transcript
2025-08-21 00:32
Telix Pharmaceuticals (TLX) H1 2025 Earnings Call August 20, 2025 07:30 PM ET Company ParticipantsKyahn Williamson - SVP - Corporate Communication & IRDarren Smith - Group CFOChristian Behrenbruch - MD, Group CEO & DirectorKevin Richardson - CEO - Telix Precision MedicineRichard Valeix - CEO - Telix TherapeuticsDavid Low - Executive DirectorNick Lorusso - VP - Biotech Equity ResearchDavid Dai - DirectorDavid Nierengarten - Managing Director - Equity ResearchConference Call ParticipantsAndy Hsieh - Research ...
Telix Pharmaceuticals Ltd(TLX) - 2025 H1 - Earnings Call Transcript
2025-08-21 00:30
Financial Data and Key Metrics Changes - Group revenues improved by 63% year on year, reaching $390 million, driven by growth in Elucix and the addition of third-party revenue from RLS [7][8][9] - Precision medicine revenues increased by 30% year on year, with EBITDA improving by 24% [7][8] - Gross margins in the precision medicine business remained stable at 64%, while the group's gross margin was 53% [8][11] Business Line Data and Key Metrics Changes - The precision medicine business saw a revenue increase of 29%, with adjusted EBITDA improving by $20 million year on year [12][13] - RLS contributed $79 million in revenues, with gross margins at 7% [14][15] - Selling and marketing expenses increased to 13% of revenue from 10% last year, reflecting preparations for product and geographic expansion [11] Market Data and Key Metrics Changes - The company secured marketing authorizations for Elucix in over 23 countries, with ongoing launches in key markets like France, Germany, Italy, and Spain [42][43] - The global rollout of Elucix is progressing well, with strong uptake in the UK following its launch [41][42] Company Strategy and Development Direction - The company is focused on four strategic pillars: expanding precision medicine, delivering on late-stage therapeutics, building a next-generation pipeline, and expanding global delivery infrastructure [4][17] - The acquisition of RLS is seen as a strategic investment to enhance US presence and improve manufacturing capabilities [27][31] - The company aims to transition from a single product to a multi-product, multi-region organization, leveraging its global infrastructure for future therapeutic rollouts [23][26] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of maintaining operational efficiency and investing in R&D to support long-term growth [8][19] - The company is committed to building long-term asset value rather than optimizing near-term EPS growth, focusing on strategic investments to unlock the full potential of its pipeline [19][20] - Management expressed confidence in the company's ability to navigate the current operating environment and continue delivering value to shareholders [74] Other Important Information - The company is responding to an SEC subpoena regarding disclosure activities related to prostate cancer therapeutic candidates, clarifying that there are no allegations or charges against the company [36] - The company is focused on maintaining a healthy cash position, ending the half-year with $27 million in cash on hand [8][16] Q&A Session Summary Question: Outlook for gross margins and impact of PSMA pricing changes - Management noted that Elucix's gross margin remained consistent at 64%, while RLS achieved a 7% gross margin [79][80] - The integration of RLS is expected to improve gross margins as more Elucix products are distributed through the RLS network [81] Question: Guidance and growth of Elucix moving forward - Management confirmed that July 1 marked the end of pass-through status for one product, but reported 7% growth quarter on quarter in volume [86][87] - The company is implementing a stabilization strategy to bridge the gap between products coming off and gaining reimbursement [88][89] Question: Launch readiness for Zurkayx - The commercial team is prepared for the launch, leveraging existing customer relationships from Elucix [94][96] - An expanded access program has been successful, indicating strong market readiness for Zurkayx [95][96]
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth
Globenewswire· 2025-08-21 00:22
Group Performance - Telix Pharmaceuticals reported a revenue of $390.4 million for H1 2025, representing a 63% increase compared to H1 2024's $239.6 million [5][8] - The group gross profit margin was 53%, reflecting a change in product mix to include third-party RLS sales, while the Illuccix® margin remained stable [5] - Adjusted EBITDA was $21.1 million, down from $37.1 million in H1 2024, attributed to increased operating expenditures from strategic acquisitions and investments [5][8] Precision Medicine Segment - Revenue from the Precision Medicine segment increased by 30% compared to H1 2024, driven by higher Illuccix dose volumes [5] - Illuccix gross margin remained stable at 64% [5] - Selling and marketing expenses rose to $40.9 million due to investments in commercial infrastructure for new product launches [5] Manufacturing Solutions - Telix Manufacturing Solutions (TMS) reported $109.5 million in revenue, with $79.0 million from third-party PET and SPECT product sales [5] - Operating expenses for TMS were $30.5 million, which included $14.9 million for the RLS business and $15.6 million for start-up and integration activities [5] - TMS facilities are located in the U.S., Belgium, Australia, and Japan, enhancing global production capabilities [5] Research and Development - Total R&D investment was $81.6 million, a 47% increase year-over-year, with 54% allocated to the therapeutics pipeline [5] - Key milestones included the completion of target enrollment for Phase 3 studies and approvals for new therapeutic studies [5][6] - Full year R&D investment guidance is maintained, expecting a year-over-year increase of 20% to 25% compared to FY 2024 [10] Financial Guidance - The company confirmed FY 2025 revenue guidance of $770 million to $800 million, reflecting expected contributions from Illuccix sales and RLS [10] - Positive operating net cash flow of $17.7 million was reported, with a cash balance of $207.2 million following significant M&A investments [5]
Telix Pharmaceuticals Ltd(TLX) - 2025 H1 - Earnings Call Presentation
2025-08-20 23:30
For personal use only H1 2025 Results Telix Pharmaceuticals ASX: TLX | NASDAQ: TLX 21 August 2025 Disclaimer This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX) and the U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this presentation is not intended to be an offer for subscription, invitation or ...
Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena – Hagens Berman
GlobeNewswire News Room· 2025-08-12 17:16
Core Viewpoint - Telix Pharmaceuticals Limited is under investigation by the SEC, leading to a significant drop in the price of its American Depositary Shares after the announcement on July 23, 2025 [1][4]. Group 1: SEC Investigation - The SEC is investigating Telix regarding its disclosures related to the development of its prostate cancer therapeutic candidates [4]. - The investigation was triggered by Telix's announcement on July 22, 2025, which revealed the SEC's scrutiny [4]. Group 2: Shareholder Response - Hagens Berman, a national shareholders rights firm, has initiated an investigation to determine if Telix misled investors about its drug candidates [2][5]. - The firm is encouraging investors who have suffered substantial losses to come forward and submit their losses [2][5]. Group 3: Whistleblower Information - Individuals with non-public information about Telix are encouraged to assist in the investigation or consider the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery [7].
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
GlobeNewswire News Room· 2025-08-09 15:53
Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited regarding potential securities fraud or unlawful business practices [1] - On July 22, 2025, Telix received a subpoena from the U.S. Securities and Exchange Commission related to disclosures about its prostate cancer therapeutic candidates, leading to a significant drop in its ADR price [3] Group 1 - The investigation by Pomerantz LLP focuses on whether Telix and its officers or directors have engaged in unlawful business practices [1] - Following the SEC subpoena, Telix's ADR price fell by $1.70, or 10.44%, closing at $14.58 on July 23, 2025 [3]
Telix H1 2025 Results: Investor Webcast Notification
Globenewswire· 2025-07-29 22:58
Company Overview - Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies [2] - The company is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan [2] - Telix aims to address significant unmet medical needs in oncology and rare diseases through its portfolio of clinical and commercial stage products [2] Financial Results Announcement - Telix will release its financial results for the half-year ended 30 June 2025 on Thursday, 21 August 2025 [1] - An investor webcast and conference call is scheduled for 9.30 am AEST on the same day [1] - Participants can register for the webcast and teleconference through provided links [1]
Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman
GlobeNewswire News Room· 2025-07-29 20:10
SAN FRANCISCO, July 29, 2025 (GLOBE NEWSWIRE) -- On July 23, 2025, investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) saw the price of their American Depositary Shares significantly fall after the company revealed that it received a subpoena from the SEC. Telix’s revelation has prompted national shareholders rights firm Hagens Berman to open an investigation into whether Telix may have misled investors about certain of its drug candidates and urges Telix investors who suffered substantial losses to su ...